Search clinical trials for: Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS

Total 14 results

Butantan Institute
University of Sao Paulo; Insituto Adolfo Lutz; Centro de Referencia e Treinamento...

Completed

Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants

Immunocompromised Patients | Safety of Pandemic Influenza A (H1N1)Vaccine | Immunogenicity of Pandemic Influenza A (H1N1)Vaccine

Brazil
National Institute of Allergy and Infectious Diseases...

Completed

Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

Influenza

United States
Paolo Corradini
University of Milan

Completed

Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients

Lymphoma | Multiple Myeloma | Myeloproliferative Disease

Italy
Immune Targeting Systems Ltd

Completed

Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers

Influenza A

Belgium
WCCT Global
National Institutes of Health (NIH); Stanford University

Completed

Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus

Influenza
GlaxoSmithKline

Completed

Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults

Influenza | Influenza Vaccines

Taiwan, Hong Kong, Thailand, Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infections

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly

Influenza | Orthomyxoviridae Infections

Belgium, United Kingdom
Immune Targeting Systems Ltd

Completed

Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge

Influenza A

United Kingdom
National Taiwan University Hospital

Unknown

Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients

Serology Analysis | Novel H1N1 Influenza Vaccination | Pediatric Haemato-oncology Patients

Taiwan
Crucell Holland BV

Completed

Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains

Influenza

Switzerland
Crucell Holland BV

Completed

Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)

Influenza

Switzerland
GlaxoSmithKline

Completed

Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

Influenza

Korea, Republic of

Search clinical trials for: Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations